Document is current
Any future updates will be listed below
-
Authors
Lee, Sohyon https://orcid.org/0000-0003-4790-4990
Weiss, Tobias https://orcid.org/0000-0002-5533-9429
Bühler, Marcel https://orcid.org/0000-0001-9608-1316
Mena, Julien https://orcid.org/0000-0001-8040-810X
Lottenbach, Zuzanna
Wegmann, Rebekka https://orcid.org/0000-0001-9616-3303
Sun, Miaomiao
Bihl, Michel
Augustynek, Bartłomiej
Baumann, Sven P.
Goetze, Sandra https://orcid.org/0000-0001-6880-8020
van Drogen, Audrey
Pedrioli, Patrick G. A.
Penton, David
Festl, Yasmin
Buck, Alicia
Kirschenbaum, Daniel
Zeitlberger, Anna M.
Neidert, Marian C.
Vasella, Flavio
Rushing, Elisabeth J.
Wollscheid, Bernd
Hediger, Matthias A.
Weller, Michael https://orcid.org/0000-0002-1748-174X
Snijder, Berend https://orcid.org/0000-0003-3386-6583
- License Information
-
More Information
Article History
Received: 6 December 2023
Accepted: 31 July 2024
First Online: 20 September 2024
Competing interests
: B.S. is scientific co-founder and shareholder of Prevision Medicine AG and Graph Therapeutics. T.W. has received honoraria from Philogen. M.C.N. received a research grant from Novocure and honoraria for consulting or lectures from WISE, Merck Sharp & Dohme, Osteopore and Novocure. M.W. has received research grants from Novartis, Quercis and Versameb and honoraria for lectures or advisory board participation or consulting from Anheart, Bayer, Curevac, Medac, Neurosense, Novartis, Novocure, Orbus, Pfizer, Philogen, Roche and Servier. The other authors declare no competing interests.
